Biogen’s BIIB080 Tau Reduction Triggers Midyear Readout, LEQEMBI Adoption Climbs
Biogen’s BIIB080 Phase 1b trial showed promising tau reduction, prompting a midyear proof-of-concept readout that could advance its Alzheimer’s portfolio. High-dose SPINRAZA has launched in the US, Japan and Europe with positive uptake, while CMS approval of blood-based biomarkers is boosting LEQEMBI adoption and potential Kisunla-to-LEQEMBI patient switches.
1. BIIB080 Phase 1b Trial
Biogen’s BIIB080 is an antisense oligonucleotide targeting tau protein. The Phase 1b trial demonstrated encouraging tau level reductions, prompting a planned proof-of-concept study with data expected midyear to assess cognitive benefit and optimal dosing regimens.
2. SPINRAZA High-Dose Approval
Biogen has secured US, Japan and European approvals for its high-dose SPINRAZA formulation. Initial patient uptake has been strong, supported by positive feedback from physicians and expanded market access.
3. LEQEMBI Biomarkers and Kisunla Switch
Recent CMS guidelines now allow blood-based biomarker tests for Alzheimer’s confirmation, boosting adoption of LEQEMBI in a primary care pilot. Physicians are increasingly considering switches from Kisunla to LEQEMBI maintenance, although Biogen has not disclosed exact patient numbers.
4. LITIFILIMAB and Pipeline Strategy
Biogen expects two Phase 3 readouts for LITIFILIMAB in systemic lupus erythematosus later this year and is evaluating filing strategies based on total data. Management also highlighted SYFOVRE’s significant lesion growth reduction in geographic atrophy and confirmed a focus on early-stage R&D with opportunistic M&A post-Apellis acquisition.